parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.32 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in bergmann glia	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	5 pathways; mostly growth signalling	0.60

No case: the score is under the bar. Receipt 1099

receipt 1106: TJP2 in dopamine neurons, braak

power: full sample +0.10 (p 0.683, n 18), 95% CI -0.38 to +0.54. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.07 (p 0.774, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.03 (p 0.922, n 18). could be the mix.
skeptic: leave-one-out range +0.02 to +0.26, sign flips 0; without severely affected donors +0.10 (p 0.683, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for TJP2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 1105: TJP2 in astrocytes, braak

power: full sample +0.09 (p 0.709, n 18), 95% CI -0.39 to +0.54. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.08 (p 0.748, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.06 (p 0.814, n 18). could be the mix.
skeptic: leave-one-out range -0.01 to +0.26, sign flips 1; without severely affected donors +0.09 (p 0.709, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for TJP2 in astrocytes.

case closed: nothing better to follow up.

loading the receipts